Capricor Therapeutics vs Crispr Therapeutics
Capricor Therapeutics and Crispr Therapeutics are similar in size: $0 and $3.5m of revenue in their latest fiscal years. Crispr Therapeutics grew faster (-90.6% against -100.0%). Capricor Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Capricor TherapeuticsCAPR, 2025 | Crispr TherapeuticsCRSP, 2025 |
|---|---|---|
| Revenue | $0 | $3.5m |
| Revenue growth | -100.0% | -90.6% |
| Net income | −$105m | −$582m |
| Operating margin | — | -18933.6% |
| Net margin | — | -16569.8% |
| Return on equity | -46.6% | -30.2% |
| Free cash flow | −$72.7m | −$346m |
| Cash | $288m | $348m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 231 | — |
| Market value | $478m | $4.83bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 13 sales | 0 buys, 30 sales |